DSM B.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
07 aug 2012 - 07:27
Statutaire naam
DSM B.V.
Titel
DSM reports robust Q2 in challenging environment
Bericht
- Q2 EBITDA from continuing operations €290 million (Q2 2011: €339 million)
- Life Sciences continues to deliver robust performance, driven by Nutrition
- Materials Sciences improved, except for caprolactam which had an EBITDA impact of - €70 million
- Q2 cash flow from operating activities at €197 million, higher than comparable and prior quarter
- Profit Improvement Program announced: expected annual EBITDA benefits of €150 million by 2014
- Interim dividend of €0.48 declared, in line with DSM's dividend policy
- Outlook 2012 largely unchanged with the exception of caprolactam
Gerelateerde downloads
Datum laatste update: 21 december 2025